- More Evidence Bolsters the Oral Herpes and Alzheimer’s Link
- Health Advocates Are Unhappy with FDA Guidance on Lead Levels in Baby Food
- FDA Calls for Better Accuracy of Pulse Oximeters in People of Color
- Fluoride May Be Linked to Decreased IQ, Says “Limited Data,” Hard-to-Interpret Study
- First U.S. Death From Bird Flu Reported in Louisiana
- Blood Test May Help Predict How Long Immunity Lasts
- DoxyPEP Lowers Rate of Sexually Transmitted Infections (STIs), Data Suggests
- Multilingual Children with Autism Show Improved Cognitive Function
- Access to Medical Test Results Is Confusing, Anxiety-Provoking
- Caregivers Face Mental, Physical Health Risks
3.6 Million Americans Could Be Covered for Wegovy Under New Medicare Rules
New Medicare rules could make 3.6 million Americans — or even more — eligible for treatment with the pricey weight-loss drug Wegovy, a new study finds.
Under the new rules, the government will pay for Wegovy treatment if a person with high BMI also has heart disease.
Until now, federal regulations have restricted Medicare from covering drugs prescribed solely for weight loss, researchers noted.
For this study, researchers analyzed data from people 65 and older who took part in a federal health and nutrition survey between 2011 and 2020.
Maximum annual costs to Medicare could be as high as $34 billion if Wegovy is prescribed to all patients with high BMI and a history of heart attack, stroke, hardened arteries or chest pain, the data show.
Wegovy has a list price of about $1,350 for a 28-day supply, according to GoodRx.com.
But even if heart disease is more narrowly defined by federal regulators, covering Wegovy (semaglutide) looks to be a budget-buster for the Medicare program, researchers said.
Under a narrow definition of heart disease, “only 1 in 7 Medicare beneficiaries with elevated BMI are likely to be eligible to receive semaglutide, but costs to Medicare could still exceed $10 billion per year,” said lead researcher Dr. Alexander Chaitoff with the Brigham and Women’s Hospital Center for Healthcare Delivery Sciences.
The findings were published Aug. 26 in the Annals of Internal Medicine.
“In this conservative coverage scenario, that means most beneficiaries with elevated BMI and cardiovascular risk would remain ineligible for semaglutide, yet the medication could still potentially become one of the costliest drugs to Medicare,” Chaitoff said in a hospital news release.
More information
The University of California, Davis, has more about semaglutide for weight loss.
SOURCE: Brigham and Women’s Hospital, news release, Aug. 26, 2024
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.
Related
-
Estrogen May Trigger Binge Drinking, Prelim Study SuggestsA woman’s binge drinking might be related to her...
- December 31, 2024
-
Some Abortion Pill Users Surprised By Pain, Study SaysAbortion pills are safe and effective, but some pain...
- December 20, 2024
-
FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box WarningThe U.S. Food and Drug Administration (FDA) has issued...
- December 18, 2024
-
Non-heterosexual Women Report Better Sexual Functioning During Midlife
TUESDAY, Dec. 17, 2024 A woman’s sex drive often...
- December 18, 2024
